Crinetics Pharmaceuticals, Inc. — Director's Dealing 2025

Feb 24, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2025-02-20

Reporting Person: Betz Stephen F. (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-20	Common Stock	A	43000	—	Acquired	114358	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-20	Stock Option (Right to Buy)	$36.86	A	65000	Acquired	2035-02-19	Common Stock (65000)	Direct

Footnotes

F1: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2026.

F2: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 20, 2025.